Home » Ketamine treatment in Spain

Ketamine treatment in Spain

ketamine treatment Spain therapy

In recent years, ketamine clinics in Spain have established themselves as a real therapeutic alternative for people with treatment-resistant depression and other mood disorders. Far from being a passing fad, these medical centres give ketamine or its derivative esketamine (Spravato®) within a safe, regulated clinical framework supervised by mental health specialists.

For many patients who have tried multiple antidepressants without success — and who often live with severe symptoms for years — these clinics, and also hospitals, offer a route to treatment backed by solid scientific evidence and increasingly accessible in cities such as Barcelona, Madrid, Seville, Vigo and Mallorca. Although ketamine has been known for decades as an anaesthetic, its use at sub-anaesthetic doses has shown rapid and significant effects on depression, especially in cases resistant to several lines of medication.

What is a ketamine clinic?

A ketamine clinic is a health centre specifically authorised to administer ketamine intravenously or intramuscularly, as well as intranasal esketamine. The key difference from other mental health spaces is that these administrations are considered invasive medical procedures, which require:

  • Specific health authorisation for parenteral procedures.
  • Equipment for monitoring vital signs (blood pressure, pulse, saturation).
  • Trained staff (doctors, nurses) to handle emergencies or adverse effects.

Not every psychology practice or therapy centre can offer these treatments. On the contrary, the premises must meet strict health regulations.

How these clinics work

In clinical practice, giving intranasal esketamine (Spravato®) follows a structured protocol designed to ensure both patient safety and therapeutic effectiveness. The process begins with an individual assessment. Before each session, a psychiatrist — or a multidisciplinary team — reviews the patient’s medical history, confirms that it is a case of resistant depression (that is, that at least two previous treatments have failed) and rules out possible contraindications. These include uncontrolled high blood pressure, closed-angle glaucoma and certain psychotic disorders.

Once treatment is approved, esketamine is given in a specially equipped room, where the patient reclines in a comfortable armchair under continuous supervision. The environment is carefully designed: dim lighting, soft music and a calm setting that helps reduce anxiety.

During and after administration — which for Spravato® can last up to two hours — the clinical team monitors the patient’s vital signs every 15 to 30 minutes. In some cases, transient rises in blood pressure or episodes of mild sedation are observed, and these usually resolve without intervention.

After the session, the patient moves to a recovery area, also kept in low light and free of outside stimuli, where they rest until the acute effects have passed. Discharge is accompanied, always with clear recommendations: do not drive, avoid alcohol and prioritise rest over the following hours.

Beyond the pharmacological act, the clinical approach seeks to integrate the experience within a broader therapeutic framework. In many cases, complementary psychological support is offered before, during and after treatment. The ultimate aim is not just to give a medicine, but to foster an environment that maximises clinical benefit and minimises the associated risks.

What ketamine clinics help with

Clinics specialising in ketamine and esketamine offer an effective alternative for people with treatment-resistant depression, that is, who have not improved after trying at least two different antidepressants for a minimum of six to eight weeks. But the clinical benefits are not limited to this diagnosis.

In recent years its use has also been extended to bipolar depressive disorder (in its depressive phase), post-traumatic stress disorder (PTSD) and some forms of chronic pain associated with depression, such as fibromyalgia or neuropathic pain.

One of the most notable aspects of this approach is its rapid therapeutic effect. Unlike conventional antidepressants — which usually take several weeks to work — ketamine can bring noticeable changes in mood, energy levels or suicidal ideation within hours or a few days. This speed of action has been validated by several meta-analyses and randomised clinical trials.

It has also been observed that between 40% and 60% of patients who did not respond to previous treatments achieve a significant improvement with ketamine, and up to 30% can reach temporary remission of symptoms. For many people this means regaining daily functioning, improving personal relationships and restarting postponed life projects.

The mechanism of action also makes a difference: by acting on NMDA receptors in the glutamatergic system, ketamine stimulates neuroplasticity processes, helping new neural connections form. This opens what many specialists describe as a “therapeutic window” that can boost the effectiveness of psychotherapy if properly integrated.

Given at sub-anaesthetic doses and under medical supervision, ketamine shows a favourable safety profile. Although effects such as mild sedation or transient rises in blood pressure can occur, these are usually manageable in well-prepared clinical settings.

Why do they offer a different kind of solution?

Ketamine clinics stand out by offering a multidimensional approach compared with traditional models of mental health care. They do not simply administer a drug, but create a comprehensive therapeutic framework that aims to speed up emotional recovery, especially in highly complex clinical cases.

One of the main advantages is speed of action. In many patients, effects begin to show after the first or second session, which is crucial in urgent situations such as suicide risk. This immediacy contrasts with the usual delay of selective serotonin reuptake inhibitors (SSRIs) or norepinephrine reuptake inhibitors (SNRIs), which can take weeks to work.

In addition, ketamine promotes greater synaptic plasticity, a phenomenon that, according to several studies, lasts for seven to fourteen days after each session. This “neurobiological opening period” can significantly boost the effects of psychological therapies such as cognitive behavioural therapy (CBT) or EMDR, when they are strategically integrated.

The approach is also characterised by flexibility and personalisation. Treatment plans are adapted to each person’s needs, combining, for example, six intensive infusions over two or three weeks with monthly maintenance sessions.

The whole process is carried out under strict medical supervision, which allows immediate action in case of mild adverse effects such as dizziness, nausea or dissociation. Specific protocols are also applied to control temporary rises in blood pressure, one of the most common reactions.

In short, ketamine is not presented as a substitute for psychotherapy or psychosocial support, but as a catalyst that speeds up processes of change. By integrating its use in a safe, personalised and supported setting, these clinics open new possibilities of recovery for people who have exhausted other paths.

Routes of administration in Spain

In the Spanish clinical context, ketamine and esketamine can be given by three main routes, each with its own indications, requirements and protocols.

Intravenous (IV) ketamine is given as a slow infusion — usually at a dose of 0.5 mg/kg over 40 to 60 minutes — in specialised clinical settings. This format requires continuous monitoring and is usually organised in intensive protocols of six sessions spread over two or three weeks, followed by maintenance sessions adjusted to the clinical response. It is a route especially suited to patients who need a precise, finely adjusted approach.

Intramuscular (IM) ketamine, less common in Spain but increasingly used in private clinics, is given by direct injection into the muscle, usually the deltoid or the buttock. The dose is usually calculated by weight (for example 0.7–1 mg/kg), and its onset of action is faster than intravenous, although with less scope for fine adjustment. It also requires medical supervision, especially during the first 60 to 90 minutes after administration, because of possible transient effects such as dissociation, nausea or raised blood pressure. It is considered particularly for patients who do not tolerate infusions well or in outpatient settings with less technical infrastructure.

Intranasal esketamine (Spravato®), authorised by the European Medicines Agency (EMA), is given as a nasal spray in accredited hospitals and health centres. Doses range from 28 to 84 mg per session, given once or twice a week during the initial phase. This treatment must be combined with an oral antidepressant, and requires clinical observation for at least two hours after each administration.

In both cases, the clinical protocol requires that discharge always takes place with accompaniment, guaranteeing the patient’s safety and avoiding the risks associated with the residual effects of the session.

The most relevant ketamine clinics in Spain

  • Clínica Synaptica (Barcelona). Integrates assisted therapy (preparation, support, integration). Trains professionals in psychedelic protocols.
  • NYKET Center Europe (Madrid). IV infusions for severe depression and suicide risk, standardised protocols.
  • KetaminPlus/Humanline (Mallorca/Andalusia). Multimodal (ketamine + psychotherapy + neurofeedback) for PTSD and complex depression.
  • Hospital units (Bellvitge). Spravato® in public programmes with neuromodulation.

Working models

Clinics offering ketamine or esketamine treatment in Spain operate under two main models, which define not only the logistics of treatment but also its therapeutic depth.

The technical model focuses on a protocolised medical intervention: psychiatric assessment, drug administration and clinical monitoring. This approach seeks rapid symptom relief in cases of resistant depression, suicidal ideation or states of emotional blockage.

The ketamine-assisted therapy model, by contrast, takes a more comprehensive approach. Besides assessment and medical safety, it prioritises preparing the patient psychologically before the session, adjusting the environment (set and setting), and offering spaces for therapeutic integration afterwards. This model favours processes of deep change when combined with psychotherapeutic approaches such as CBT, EMDR or body-oriented therapies.

Safety and regulation

The clinical use of ketamine and esketamine is strictly regulated in Spain. It can only be given in authorised health centres, which must have accredited professionals and adequate means for monitoring vital signs and safely managing adverse effects, such as dissociation or spikes in blood pressure.

In the case of intranasal esketamine (Spravato®), its use is limited to hospitals and specifically accredited clinics, following the protocols defined by the European Medicines Agency and national regulations.

Regulatory compliance is no minor detail: it guarantees that the environment is safe, that the medical indication is respected, and that there are clear protocols for action in case of any incident.

How to choose a ketamine clinic

Choosing the right clinic to start ketamine treatment involves more than comparing prices or locations. There are objective criteria that can guide the decision in an informed and safe way:

  • Verifiable health authorisation, registered with the competent authorities.
  • A qualified clinical team, with psychiatrists and staff with specific experience in ketamine.
  • A clear therapeutic model, either technical or assisted, according to the patient’s needs.
  • Transparent protocols, including prior assessment, follow-up and ways to get in touch in case of doubts or adverse effects.
  • Realistic expectations, avoiding exaggerated promises or “miracle cure” talk.

An initial phone call can be enough to resolve key questions and gauge how professional and supportive the clinic is.

Keep reading

Funded by the European Union - NextGenerationEURecovery, Transformation and Resilience Plan (Spain)

Funded by the European Union – NextGenerationEU